Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review

Journal of Pain and Symptom Management

Volumn 28, Issue 2, 2004, Pages 140-175

  Chou, Roger ^a,b   Peterson, Kim ^a   Helfand, Mark ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b Portland or 97239 USA ^*  (United States)

Author keywords

central; meta analysis; Muscle relaxants; muscle spasticity; musculoskeletal diseases

Indexed keywords

ANALGESIC AGENT; BACLOFEN; BENZODIAZEPINE; CARISOPRODOL; CHLORZOXAZONE; CLONIDINE; CYCLOBENZAPRINE; DANTROLENE; DIAZEPAM; GABAPENTIN; MEPROBAMATE; METAXALONE; METHOCARBAMOL; MUSCLE RELAXANT AGENT; ORPHENADRINE; QUININE; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ASTHENIA; BACKACHE; CLINICAL TRIAL; DATA BASE; DEATH; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INDUSTRY; DRUG OVERDOSE; DRUG QUALITY; DRUG SAFETY; FATIGUE; FOOD AND DRUG ADMINISTRATION; HALLUCINATION; HEADACHE; HEPATITIS; HUMAN; JAUNDICE; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; META ANALYSIS; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE WEAKNESS; MUSCULOSKELETAL DISEASE; MYALGIA; NECK PAIN; REVIEW; SEDATION; SEIZURE; SKELETAL MUSCLE; SOMNOLENCE; SPASTICITY; SYSTEMATIC REVIEW; VALIDATION PROCESS; WITHDRAWAL SYNDROME; XEROSTOMIA;

CLINICAL TRIALS; COMORBIDITY; EVIDENCE-BASED MEDICINE; HUMANS; MOTOR NEURON DISEASE; MUSCLE SPASTICITY; MUSCULOSKELETAL DISEASES; NEUROMUSCULAR AGENTS; PERIPHERAL NERVOUS SYSTEM DISEASES; TREATMENT OUTCOME;

EID: 3242786494     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2004.05.002     Document Type: Review

References (160)

1. Young R.R. Spasticity: a review. Neurology. 44:(11 Suppl 9):1994;S12-S20
2. Andersson P.B., Goodkin D.E. Current pharmacologic treatment of multiple sclerosis symptoms. West J Med. 165:(5):1996;313-317
3. Burchiel K.J., Hsu F.P. Pain and spasticity after spinal cord injury: mechanisms and treatment. Spine. 26:(24 Suppl):2001;S146-S160
4. Barnes M.P. Medical management of spasticity in stroke. Age Ageing. 30:(Suppl. 1):2001;13-16
5. Anonymous. Spasticity. Lancet. 2:(8678-8679):1989;1488-1490
6. Leventhal L.J. Management of fibromyalgia. Ann Intern Med. 131:(11):1999;850-858
7. Redillas C., Solomon S. Prophylactic pharmacological treatment of chronic daily headache. Headache. 40:(2):2000;83-102
8. Deyo R.A., Bergman J., Phillips W.R. Drug therapy for back pain: Which drugs help which patients? Spine. 21:(24):1996;2840-2850
9. Arnold L.M., Keck P.E. Jr., Welge J.A. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics. 41:(2):2000;104-113
10. Cherkin D.C., Wheeler K.J., Barlow W., et al. Medication use for low back pain in primary care. Spine. 23:(5):1998;607-614
11. Brogden R.N., Speight T.M., Avery G.S. Baclofen: a preliminary report of its pharmacological properties and therapeutic efficacy in spasticity. Drugs. 8:(1):1974;1-14
12. Davidoff R.A. Antispasticity drugs: mechanisms of action. Ann Neurol. 17:(2):1985;107-116
13. Wagstaff A.J., Bryson H.M. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 53:(3):1997;435-452
14. Nance P.W. Tizanidine: An α2-agonist imidazoline with antispasticity effects. Today's Ther Trends. 15:(1):1997;11-25
15. Kita M., Goodkin D.E. Drugs used to treat spasticity. Drugs. 59:(3):2000;487-495
16. Cook J.B., Nathan P.W. On the site of action of diazepam in spasticity in man. J Neurol Sci. 5:(1):1967;33-37
17. Davidoff R.A. Pharmacology of spasticity. Neurology. 28:(9 Pt 2):1978;46-51
18. ™) and cyclobenzaprine (Flexeril(TM)) in acute musculoskeletal conditions. Today's Ther Trends. 1:(4):1984;1-11
19. Reeves R.R., Carter O.S., Pinkofsky H.B., et al. Carisoprodol (soma): abuse potential and physician unawareness. J Addict Dis. 18:(2):1999;51-56
20. Azoury F.J. Double-blind study of Parafon Forte and Flexeril in the treatment of acute skeletal muscle disorders. Curr Ther Res. 26:1979;189-197
21. Gold R.H. Orphenadrine citrate: Sedative or muscle relaxant? Clin Ther. 1:(6):1978;451-453
22. Smith H.S., Barton A.E. Tizanidine in the management of spasticity and musculoskeletal complaints in the palliative care population. Am J Hosp Palliat Care. 17:(1):2000;50-58
23. ™ and Flexeril(TM) in the treatment of acute skeletal muscle disorders of local origin. Curr Ther Res. 28:(2):1980;164-172
24. Miller A.R. A comparative study of Parafon Forte tablets and Soma compund in the treatment of painful skeletal muscle conditions. Curr Ther Res Clin Exp. 19:(4):1976;444-450
25. Gready D.M. Parafon Forte versus Robaxisal in skeletal muscle disorders: a double-blind study. Curr Ther Res Clin Exp. 20:(5):1976;666-673
26. Walker J.M. Value of an acetaminophen-chlorzoxazone combination (Parafon Forte) in the treatment of acute musculoskeletal disorders. Curr Ther Res, Clin Exp. 15:(5):1973;248-252
27. Vernon W.G. A double-blind evaluation of Parafon Forte in the treatment of musculo-skeletal back conditions. Curr Ther Res, Clin Exp. 14:(12):1972;801-806
28. Middleton R.S. A comparison of two analgesic muscle relaxant combinations in acute back pain. Br J Clin Pract. 38:(3):1984;107-109
29. Santandrea S., Montrone F., Sarzi-Puttini P., et al. A double-blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res. 21:(2):1993;74-80
30. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 192:1964;540-542
31. Bohannon R.W., Smith M.B. Inter rater reliability of a modified Ashworth Scale of muscle spasticity. Phys Ther. 67:1987;206-207
32. Sharrack B., Hughes R.A.C. Clinical scales for multiple sclerosis. J Neurol Sci. 135:1996;1-9
33. Simms R.W., Felson D.T., Goldenberg D.L. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol. 18:(10):1991;1558-1563
34. Mannerkorpi K., Ekdahl C. Assessment of functional limitation and disability in patients with fibromyalgia. Scand J Rheumatol. 26:(1):1997;4-13
35. Chan C.H. Dantrolene sodium and hepatic injury. Neurol. 40:(9):1990;1427-1432
36. Stien R., Nordal H.J., Oftedal S.I., et al. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen. Acta Neurol Scand. 75:(3):1987;190-194
37. Anonymous. 2003. Methods for drug class reviews for Oregon Health Plan Practitioner-Managed Prescription Drug Plan. Oregon Evidence-based Practice Center, Portland, OR. Available at: http://www.oregonrx.org/OrgrxPDF/ Skeletal%20Muscle% 20Relaxants/Revised%20EPC%20Reprt%204-9-03/ App%20C%20OHP%20Methods%202003.pdf.
38. Harris R.P., Helfand M., Woolf S.H., et al. Current methods of the third U.S. Preventive Services Task Force. Am J Prev Med. 20:(3S):2001;21-35
39. Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews CRD Report Number 4. 2nd edition :2001;NHS Centre for Reviews and Dissemination, York, UK. Report No.: 4 (2nd edition)
40. Mulrow CD, Oxman A. How to conduct a Cochrane systematic review. Version 3.0.2.
41. Shakespeare D.T., Boggild M., Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews. (4):2001;CD001332
42. Browning R., Jackson J.L., O'Malley P.G. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med. 161:(13):2001;1613-1620
43. Lataste X., Emre M., Davis C., et al. Comparative profile of tizanidine in the management of spasticity. Neurology. 44:(11 Suppl 9):1994;S53-S59
44. Taricco M., Adone R., Pagliacci C., et al. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database of Systematic Reviews. (2):2000;CD001131
45. Wallace J.D. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology. 44:(11 Suppl 9):1994;S60-S68. Discussion S68-S69
46. Groves L., Shellenberger M.K., Davis C.S. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 15:(4):1998;241-251
47. Nibbelink D.W., Strickland S.C., McLean L.F., et al. Cyclobenzaprine, diazepam and placebo in the treatment of skeletal muscle spasm of local origin. Clin Ther. 1:(6):1978;409-424
48. Nogen A.G. Medical treatment for spasticity in children with cerebral palsy. Child Brain. 2:(5):1976;304-308
49. Bes A., Eyssette M., Pierrot-Deseilligny E., et al. A multi-center, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia. Curr Med Res Opin. 10:(10):1988;709-718
50. Nance P.W. A comparison of clonidine, cyproheptadine and baclofen in spastic spinal cord injured patients. J Am Paraplegia Soc. 17:(3):1994;150-156
51. Medici M., Pebet M., Ciblis D. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions. Curr Med Res Opin. 11:(6):1989;398-407
52. Roussan M., Terrence C., Fromm G. Baclofen versus diazepam for the treatment of spasticity and long-term follow-up of baclofen therapy. Pharmatherapeutica. 4:(5):1985;278-284
53. Rinne U.K. Tizanidine treatment of spasticity in multiple sclerosis and chronic myelopathy. Curr Ther Res Clin Exp. 28:(6 I):1980;827-836
54. Glass A., Hannah A. A comparison of dantrolene sodium and diazepam in the treatment of spasticity. Paraplegia. 12:(3):1974;170-174
55. Nance P.W., Bugaresti J., Shellenberger K., et al. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology. 44:(11 Suppl 9):1994;S44-S52
56. Smolenski C., Muff S., Smolenski-Kautz S. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis. Curr Med Res Opin. 7:(6):1981;374-383
57. Hoogstraten M.C., van der Ploeg R.J., vd Burg W., et al. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients. Acta Neurol Scand. 77:(3):1988;224-230
58. Eyssette M., Rohmer F., Serratrice G., et al. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin. 10:(10):1988;699-708
59. Newman P.M., Nogues M., Newman P.K., et al. Tizanidine in the treatment of spasticity. Eur J Clin Pharmacol. 23:(1):1982;31-35
60. Bass B., Weinshenker B., Rice G.P., et al. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. Can J Neurol Sci. 15:(1):1988;15-19
61. From A., Heltberg A. A double-blind trial with baclofen (Lioresal) and diazepam in spasticity due to multiple sclerosis. Acta Neurol Scand. 51:(2):1975;158-166
62. Schmidt R.T., Lee R.H., Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry. 39:(4):1976;350-356
63. Cartlidge N.E., Hudgson P., Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci. 23:(1):1974;17-24
64. Basmajian J.V., Yucel V. Effects of a GABA-derivative (BA-34647) on spasticity. Preliminary report of a double-blind cross-over study. Am J Phys Med. 53:(5):1974;223-228
65. Basmajian J.V. Lioresal (baclofen) treatment of spasticity in multiple sclerosis. Am J Phys Med. 54:(4):1975;175-177
66. Brar S.P., Smith M.B., Nelson L.M., et al. Evaluation of treatment protocols on minimal to moderate spasticity in multiple sclerosis. Arch Phys Med Rehab. 72:(3):1991;186-189
67. Duncan G.W., Shahani B.T., Young R.R. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions. A double-blind, cross-over study. Neurology. 26:(5):1976;441-446
68. Feldman R.G., Kelly-Hayes M., Conomy J.P., et al. Baclofen for spasticity in multiple sclerosis. Double blind crossover and three year study. Neurology. 28:(11):1978;1094-1098
69. Hinderer S.R. The supraspinal anxiolytic effect of baclofen for spasticity reduction. Am J Phys Med Rehabil. 69:(5):1990;254-258
70. Hulme A., MacLennan W.J., Ritchie R.T., et al. Baclofen in the elderly stroke patient its side-effects and pharmacokinetics. Eur J Clin Pharmacol. 29:(4):1985;467-469
71. Jones K., Castleden C.M. A double-blind comparison of quinine sulphate and placebo in muscle cramps. Age Ageing. 12:(2):1983;155-158
72. McKinlay I., Hyde E., Gordon N. Baclofen: A team approach to drug evaluation of spasticity in childhood. Scott Med J. 25:(SYMP):1980;S26-S28
73. Medaer R., Hellebuyk H., Van D.B.E., et al. Treatment of spasticity due to stroke. A double-blind, cross-over trial comparing baclofen with placebo. Acta Ther. 17:(4):1991;323-331
74. Milla P.J., Jackson A.D. A controlled trial of baclofen in children with cerebral palsy. J Int Med Res. 5:(6):1977;398-404
75. Orsnes G., Crone C., Krarup C., et al. The effect of baclofen on the transmission in spinal pathways in spastic multiple sclerosis patients. Clin Neurophysiol. 111:(8):2000;1372-1379
76. Sachais B.A., Logue J.N., Carey M.S. Baclofen, a new antispastic drug. A controlled, multicenter trial in patients with multiple sclerosis. Arch Neurol. 34:(7):1977;422-428
77. Sawa G.M., Paty D.W. The use of baclofen in treatment of spasticity in multiple sclerosis. Can J Neurol Sci. 6:(3):1979;351-354
78. Basmajian J.V., Super G.A. Dantrolene sodium in the treatment of spasticity. Arch Phys Med Rehab. 54:(2):1973;61-64
79. Chyatte S.B., Birdsong J.H., Roberson D.L. Dantrolene sodium in athetoid cerebral palsy. Arch Phys Med Rehab. 54:(8):1973;365-368
80. Denhoff E., Feldman S., Smith M.G., et al. Treatment of spastic cerebral palsied children with sodium dantrolene. Dev Med Child Neurol. 17:(6):1975;736-742
81. Gambi D., Rossini P.M., Calenda G., et al. Dantrolene sodium in the treatment of spasticity caused by multiple sclerosis or degenerative myelopathies: A double-blind, cross-over study in comparison with placebo. Curr Ther Res. 33:(5):1983;835-840
82. Gelenberg A.J., Poskanzer D.C. The effect of dantrolene sodium on spasticity in multiple sclerosis. Neurology. 23:(12):1973;1313-1315
83. Haslam R.H., Walcher J.R., Lietman P.S., et al. Dantrolene sodium in children with spasticity. Arch Phys Med Rehab. 55:(8):1974;384-388
84. Joynt R.L., Leonard J.A. Jr. Dantrolene sodium suspension in treatment of spastic cerebral palsy. Dev Med Child Neurol. 22:(6):1980;755-767
85. Katrak P.H., Cole A.M., Poulos C.J., et al. Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident: a randomized double-blind study. Arch Phys Med Rehab. 73:(1):1992;4-9
86. Ketel W.B., Kolb M.E. Long-term treatment with dantrolene sodium of stroke patients with spasticity limiting the return of function. Curr Med Res Opin. 9:(3):1984;161-169
87. Luisto M., Moller K., Nuutila A., et al. Dantrolene sodium in chronic spasticity of varying etiology. Acta Neurol Scand. 65:(4):1982;355-362
88. Monster A.W. Spasticity and the effect of dantrolene sodium. Arch Phys Med Rehab. 55:(8):1974;373-383
89. Nogen A.G. Effect of dantrolene sodium on the incidence of seizures in children with spasticity. Child Brain. 5:(4):1979;420-425
90. Sheplan L., Ishmael C. Spasmolytic properties of dantrolene sodium: Clinical evaluation. Mil Med. 140:(1):1975;26-29
91. Tolosa E.S., Soll R.W., Loewenson R.B. Treatment of spasticity in multiple sclerosis with dantrolene. JAMA. 233:(10):1975;1046
92. Weiser R., Terenty T., Hudgson P., et al. Dantrolene sodium in the treatment of spasticity in chronic spinal cord disease. Practitioner. 221:(1321):1978;123-127
93. Knutsson E., Martensson, et al. Antiparetic and antispastic effects induced by tizanidine in patients with spastic paresis. J Neurol Sci. 53:(2):1982;187-204
94. Lapierre Y., Bouchard S., Tansey C., et al. Treatment of spasticity with tizanidine in multiple sclerosis. Can J Neurol Sci. 14:(3 Suppl):1987;513-517
95. Meythaler J.M., Guin-Renfroe S., Johnson A., et al. Prospective assessment of tizanidine for spasticity due to acquired brain injury. Arch Phys Med Rehab. 82:(9):2001;1155-1163
96. Smith C., Birnbaum G., Carter J.L., et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology. 44:(11 Suppl 9):1994;S34-S42. Discussion S42-S43
97. Anonymous. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology. 44:(11 Suppl 9):1994;S70-S78
98. Losin S., McKean C.M. Chlorzoxazone (Paraflex) in the treatment of severe spasticity. Dev Med Child Neurol. 8:(6):1966;768-769
99. Bjerre I., Blennow G. Methocarbamol in the treatment of cerebral palsy in children. Neuropadiatrie. 3:(2):1971;140-146
100. Ashby P., Burke D., Rao S., et al. Assessment of cyclobenzaprine in the treatment of spasticity. J Neurol Neurosurg Psychiatry. 35:(5):1972;599-605
101. Brown B.R. Jr., Womble J. Cyclobenzaprine in intractable pain syndromes with muscle spasm. JAMA. 240:(11):1978;1151-1152
102. Basmajian J.V. Cyclobenzaprine hydrochloride effect on skeletal muscle spasm in the lumbar region and neck: two double-blind controlled clinical and laboratory studies. Arch Phys Med Rehab. 59:(2):1978;58-63
103. Bragstad A., Blikra G. Evaluation of a new skeletal muscle relaxant in the treatment of lower back pain (A Comparison of DS 103-282 with Chlorzoxazone). Curr Ther Res Clin Exp. 26:(1):1979;39-43
104. Rollings H.E., Glassman J.M., Soyka J.P. Management of acute musculoskeletal conditions - Thoracolumbar strain or sprain: A double-blind evaluation comparing the efficacy and safety of carisoprodol with cyclobenzaprine hydrochloride. Curr Ther Res. 34:(6):1983;917-928
105. Boyles W.F. Management of acute musculoskelatal conditions. Todays Ther Trends. 1:1983;1-16
106. Scheiner J.J. Cyclobenzaprine in the treatment of local muscle spasm. Clinical evaluation of Flexeril. 1978;Postgraduate Medicine Communications, Minneapolis, MN. 39-48
107. Aiken D.W. A comparative study of the effects of cyclobenzaprine, diazepam and placebo in the treatment of acute musculoskeletal conditions of the low back. Clinical evaluation of Flexeril. 1978;Postgraduate Medicine Communications, Minneapolis, MN. 34-38
108. Fryda-Kaurimsky Z., Muller-Fassbender H. Tizanidine (DS 103-282) in the treatment of acute paravertebral muscle spasm: a controlled trial comparing tizanidine and diazepam. J Int Med Res. 9:(6):1981;501-505
109. Hennies O.L. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin. J Int Med Res. 9:(1):1981;62-68
110. Borenstein D.G., Lacks S., Wiesel S.W. Cyclobenzaprine and naproxen versus naproxen alone in the treatment of acute low back pain and muscle spasm. Clin Ther. 12:(2):1990;125-131
111. McGuinness B.W. A double-blind comparison in general practice of a combination tablet containing orphenadrine citrate and paracetamol ('Norgesic') with paracetamol alone. J Int Med Res. 11:(1):1983;42-45
112. Salvini S., Antonelli S., De M.G., et al. Dantrolene sodium in low back pain and cervicobrachialgia treatment: A controlled study. Curr Ther Res Clin Exp. 39:(2):1986;172-177
113. Reynolds W.J., Moldofsky H., Saskin P., et al. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia. J Rheumatol. 18:(3):1991;452-454
114. Bennett R.M., Gatter R.A., Campbell S.M., et al. A comparison of cyclobenzaprine and placebo in the management of fibrositis. A double-blind controlled study. Arthritis Rheum. 31:(12):1988;1535-1542
115. Carette S., Bell M.J., Reynolds W.J., et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: A randomized, double-blind clinical trial. Arthritis Rheum. 37:(1):1994;32-40
116. Fogelholm R., Murros K. Tizanidine in chronic tension-type headache: a placebo controlled double-blind cross-over study. Headache. 32:(10):1992;509-513
117. Lance J.W., Anthony M. Cyclobenzaprine in the treatment of chronic tension headache. Med J Aust. 2:(25):1972;1409-1411
118. Murros K., Kataja M., Hedman C., et al. Modified-release formulation of tizanidine in chronic tension-type headache. Headache. 40:(8):2000;633-637
119. Saper J.R., Lake A.E. 3rd, Cantrell D.T., et al. Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache. 42:(6):2002;470-482
120. Latta D., Turner E. An alternative to quinine in nocturnal leg cramps. Curr Ther Res Clin Exp. 45:(5):1989;833-837
121. Baratta R.R. A double-blind comparative study of carisoprodol, propoxyphene, and placebo in the management of low back syndrome. Curr Ther Res Clin Exp. 20:(3):1976;233-240
122. Cullen A.P. Carisoprodol (Soma) in acute back conditions: a double blind, randomized, placebo controlled study. Curr Ther Res Clin Exp. 20:(4II):1976;557-562
123. Hindle T.H. Comparison of carisoprodol, butabarbital, and placebo in treatment of the low back syndrome. Calif Med. 117:(2):1972;7-11
124. Soyka J.P., Maestripieri L.R. Soma compound (carisoprodol plus phenacetin and caffeine) in the treatment of acute, painful musculoskeletal conditions. Curr Ther Res. 26:(2):1979;165-180
125. Aiken D.W. Cyclobenzaprine in the treatment of acute skeletal muscle spasm of local origin. Clinical evaluation of Flexeril. 1978;Postgraduate Medicine Communications, Minneapolis, MN. 30-33
126. Baratta R.R. A double-blind study of cyclobenzaprine and placebo in the treatment of acute musculoskeletal conditions of the low back. Curr Ther Res. 32:(5):1982;646-652
127. Basmajian J.V. Acute back pain and spasm. A controlled multicenter trial of combined analgesic and antispasm agents. Spine. 14:(4):1989;438-439
128. Bercel N.A. Cyclobenzaprine in the treatment of skeletal muscle spasm in osteoarthritis of the cervical and lumbar spine. Curr Ther Res. 22:1977;462-468
129. Bianchi M. Evaluation of cyclobenzaprine for skeletal muscle spasm of local origin. Clinical evaluation of Flexeril. 1978;Postgraduate Medicine Communications, Minneapolis, MN. 25-29
130. Quimby L.G., Gratwick G.M., Whitney C.D., et al. A randomized trial of cyclobenzaprine for the treatment of fibromyalgia. J Rheumatol Suppl. 19:1989;140-143
131. Steingard P.M., Schildberg W.L., Peterson K.D. Multiclinic study of a muscle relaxant for treatment of acute musculoskeletal disorders. Osteopath Ann. 8:(10):1980;44-58
132. Valtonen E.J. A controlled clinical trial of chlormezanone, orphenadrine, orphenadrine/paracetamol and placebo in the treatment of painful skeletal muscle spasms. Ann Clin Res. 7:(2):1975;85-88
133. Dent R.W., Ervin D.K-. A study of metaxalone (Skelaxin) vs. placebo in acute musculoskeletal disorders: a cooperative study. 1975 Curr Ther Res. Clin Exp. 18:(3):1975; 443-440
134. Fathie K. A second look at a skeletal muscle relaxant: A double-blind study of metaxalone. Curr Ther Res. 6:(11):1964;677-683
135. Diamond S. Double-blind study of metaxalone; use as skeletal-muscle relaxant. JAMA. 195:(6):1966;479-480
136. Berry H., Hutchinson D.R. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res. 16:(2):1988;75-82
137. Berry H., Hutchinson D.R. Tizanidine and ibuprofen in acute low-back pain: results of a double-blind multicentre study in general practice. J Int Med Res. 16:(2):1988;83-91
138. Lepisto P. A comparative trial of DS 103-282 and placebo in the treatment of acute skeletal muscle spasms due to disorders of the back. Curr Ther Res. 26:(4):1979;454-459
139. Anonymous. Efficacy and gastroprotective effects of tizanidine plus diclofenac versus placebo plus diclofenac in patients with painful muscle spasms. Curr Ther Res. 59:(1):1998;13-22
140. Dapas F., Hartman S.F., Martinez L., et al. Baclofen for the treatment of acute low-back syndrome. A double-blind comparison with placebo. Spine. 10:(4):1985;345-349
141. Tisdale S.A.J., Ervin D.K. A controlled study of methocarbamol (Robaxin) in acute painful musculoskeletal conditions. Curr Ther Res Clin Exp. 17:(6):1975;525-530
142. Casale R. Acute low back pain. Symptomatic treatment with a muscle relaxant drug. Clin J Pain. 4:(2):1988;81-88
143. Utili R., Biotnott J.K., Zimmerman H.J. Dantrolene-associated hepatic injury: incidence and character. Gastroenterol. 72:1977;610-616
144. FDA. Accessed June 7, 2004. http://www.fda. gov/cder/foi/label/2002/ 21447lbl.pdf - Cached -. FDA. Available: 8/30/2002
145. de Graaf E.M., Oosterveld M., Tjabbes T., et al. A case of tizanidine-induced hepatic injury. J Hepatol. 25:1996;772-773
146. Rivas D.A., Chancellor M.B., Hill K., et al. Neurological manifestations of baclofen withdrawal. J Urol. 150:(6):1993;1903-1905
147. Kofler M., Arturo Leis A. Prolonged seizure activity after baclofen withdrawal. Neurology. 42:(3 Pt 1):1992;697-698
148. Garabedian-Ruffalo S.M., Ruffalo R.L. Adverse effects secondary to baclofen withdrawal. Drug Intel Clin Pharm. 19:(4):1985;304-306
149. Kirubakaran V., Mayfield D., Rengachary S. Dyskinesia and psychosis in a patient following baclofen withdrawal. Am J Psychiatry. 141:(5):1984;692-693
150. Mandac B.R., Hurvitz E.A., Nelson V.S. Hyperthermia associated with baclofen withdrawal and increased spasticity. Arch Phys Med Rehab. 74:(1):1993;96-97
151. Chen K.S., Bullard M.J., Chien Y.Y., et al. Baclofen toxicity in patients with severely impaired renal function. Ann Pharmacother. 31:(11):1997;1315-1320
152. Ghose K., Holmes K.M., Matthewson K. Complications of baclofen overdosage. Postgrad Med J. 56:(662):1980;865-867
153. Lipscomb D.J., Meredith T.J. Baclofen overdose. Postgrad Med J. 56:(652):1980;108-109
154. Zak R., Solomon G., Petito F., et al. Baclofen-induced generalized nonconvulsive status epilepticus. Ann Neurol. 36:(1):1994;113-114
155. Elder N.C. Abuse of skeletal muscle relaxants. Am Fam Physician. 44:(4):1991;1223-1226
156. Gaillard Y., Baillault F., Pepin G. Meprobamate overdosage: a continuing problem. Sensitive GC-MS quantitation after solid phase extraction in 19 fatal cases. Forensic Sci Int. 86:(3):1997;173-180
157. Nibbelink D.W., Strickland S.C. Cyclobenzaprine (Flexeril(TM)): Report of a postmarketing surveillance program. Curr Ther Res Clin Exp. 28:(6 I):1980;894-903
158. Powers B.J., Cattau E.L., Zimmerman H.J. Chlorzoxazone hepatotoxic reactions. Arch Intern Med. 146:1986;1183-1186
159. Pandyan A.D., Johnson G.R., Price C.I., et al. A review of the properties and limitations of the Ashworth and modified Ashworth Scales as measures of spasticity. Clin Rehabil. 13:(5):1999;373-383
160. Landau W.M. Tizanidine and spasticity. Neurol. 45:(12):1995;2295-2296